ClinicalTrials.Veeva

Menu

Inhibin B/AFC Ratio for Ovarian Response

I

Insemine Humen Reproduction Centre

Status

Not yet enrolling

Conditions

IVF
Ovulation Disorder
Infertility, Female

Treatments

Drug: FSH-R

Study type

Observational

Funder types

NETWORK

Identifiers

NCT06292806
001-2024

Details and patient eligibility

About

Ovarian response to gonadotropin stimulation plays a major role in the success of in vitro fertilization (IVF). Anti-müllerian hormone (AMH), inhibin B, and antral follicle count (AFC) are ovarian reserve markers and also predictors of the ovarian response, as they correlate with the number of oocytes retrieved. Ovarian responsiveness can also be assessed through the Follicular Output Rate (FORT), which evaluates the proportion of follicles that developed during stimulation by the ratio of PFC (preovulatory follicle count) to AFC. FORT highlights that some follicles do not respond to the FSH; therefore, this project proposes an endocrinological approach to this issue by relating AFC to inhibin B and AMH ㅡ hormones produced by granulosa cells, but at different stages of folliculogenesis and with endocrine and paracrine functions, respectively. The inhibin B/AFC and AMH/AFC ratios correlated with FORT and the number of oocytes retrieved may help elucidate the mechanisms involved in follicular responsiveness.

A prospective cohort study will be conducted with patients of the Insemine Center for Human Reproduction. Antral follicle count and AMH measurement will be performed before IVF cycle initiation, and inhibin B measurement will be carried out on a blood sample collected on the fifth day of ovarian stimulation. The primary outcomes will be the Follicular Output Rate (FORT) and the number of oocytes retrieved. Secondary outcomes include the number of metaphase II oocytes, oocyte quality, fertilization rate and embryo quality.

Enrollment

144 estimated patients

Sex

Female

Ages

18 to 40 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • first IVF;
  • without severe male factor involved.

Exclusion criteria

  • Patients with endometrioma;
  • ovarian cyst;
  • AMH < 0.5 ng/ml;
  • increased serum TSH (thyroid-stimulating hormone) or prolactin levels;
  • endocrinopathies;
  • previous oophorectomy;
  • failure to visualize one of the ovaries on ultrasound.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems